Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · IEX Real-Time Price · USD
0.524
-0.022 (-4.05%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Forte Biosciences Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Forte Biosciences stock have an average target of 3.38, with a low estimate of 2.75 and a high estimate of 4.00. The average target predicts an increase of 545.16% from the current stock price of 0.52.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 30, 2024.
Analyst Ratings
The average analyst rating for FBRX stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 5 | 5 | 5 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 1 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Brookline Capital | Brookline Capital | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +663.50% | May 30, 2024 |
| Ladenburg Thalmann | Ladenburg Thalmann | Hold → Strong Buy Upgrades $2.75 | Hold → Strong Buy | Upgrades | $2.75 | +424.91% | Apr 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Sell → Hold Upgrades n/a | Strong Sell → Hold | Upgrades | n/a | n/a | Sep 20, 2021 |
| Brookline Capital | Brookline Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 3, 2021 |
| Chardan Capital | Chardan Capital | Strong Buy → Strong Sell Downgrades n/a | Strong Buy → Strong Sell | Downgrades | n/a | n/a | Sep 3, 2021 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.61
from -1.00
EPS Next Year
-0.55
from -0.61
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | n/a | 34.8M |
| Avg | n/a | n/a | n/a | n/a | 16.9M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.54 | -0.43 | -0.21 | -0.17 | -0.09 |
| Avg | -0.61 | -0.55 | -0.57 | -0.52 | -0.46 |
| Low | -0.65 | -0.67 | -0.90 | -0.84 | -0.80 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.